NASDAQ:BCTX BriaCell Therapeutics (BCTX) Stock Price, News & Analysis $0.56 -0.07 (-11.10%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$0.56▼$0.6350-Day Range$0.55▼$1.0652-Week Range$0.52▼$6.38Volume3.17 million shsAverage Volume1.20 million shsMarket Capitalization$10.31 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get BriaCell Therapeutics alerts: Email Address BriaCell Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,111.4% Upside$18.00 Price TargetShort InterestHealthy1.74% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.26Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.39) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.14 out of 5 starsMedical Sector340th out of 919 stocksPharmaceutical Preparations Industry160th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingBriaCell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBriaCell Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about BriaCell Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.74% of the float of BriaCell Therapeutics has been sold short.Short Interest Ratio / Days to CoverBriaCell Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BriaCell Therapeutics has recently decreased by 39.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBriaCell Therapeutics does not currently pay a dividend.Dividend GrowthBriaCell Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCTX. Previous Next 2.9 News and Social Media Coverage News SentimentBriaCell Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for BriaCell Therapeutics this week, compared to 0 articles on an average week.Search Interest7 people have searched for BCTX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows3 people have added BriaCell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BriaCell Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.77% of the stock of BriaCell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 15.42% of the stock of BriaCell Therapeutics is held by institutions.Read more about BriaCell Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BriaCell Therapeutics are expected to grow in the coming year, from ($1.39) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BriaCell Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BriaCell Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BriaCell Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.I call these Nvidia’s “Silent Partners.” About BriaCell Therapeutics Stock (NASDAQ:BCTX)BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More BCTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCTX Stock News HeadlinesSeptember 12 at 4:05 PM | globenewswire.comBriaCell Therapeutics Announces Closing of $8.5 Million OfferingSeptember 12 at 4:39 AM | americanbankingnews.comBriaCell Therapeutics (NASDAQ:BCTX) Receives Buy Rating from HC WainwrightSeptember 15, 2024 | Weiss Ratings (Ad)Who are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.September 11, 2024 | marketwatch.comBriaCell Therapeutics Shares Retreat From Earlier Surge After Stock OfferingSeptember 11, 2024 | globenewswire.comBriaCell Therapeutics Announces $8.5 Million OfferingSeptember 11, 2024 | benzinga.comWhy Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On WednesdaySeptember 11, 2024 | globenewswire.comBriaCell Reports Positive Overall Survival (OS) in Metastatic Breast CancerSeptember 10, 2024 | globenewswire.comBriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate CancerSeptember 15, 2024 | Weiss Ratings (Ad)Who are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.September 9, 2024 | globenewswire.comBriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingAugust 15, 2024 | investing.comBriacell Therapeutics Corp (BCT)July 18, 2024 | globenewswire.comBriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast CancerJune 3, 2024 | globenewswire.comBriaCell Presents Clinical Efficacy Data at ASCO 2024May 24, 2024 | globenewswire.comBriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024May 17, 2024 | globenewswire.comBriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct OfferingMay 15, 2024 | globenewswire.comBriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct OfferingApril 24, 2024 | globenewswire.comBriaCell Announces Oral and Poster Presentations at ASCO 2024April 10, 2024 | globenewswire.comBriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate CancerSee More Headlines Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/14/2024Today9/15/2024Next Earnings (Estimated)10/23/2024Fiscal Year End7/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BCTX CUSIPN/A CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+3,111.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,300,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-37.35% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.24) per share Price / Book-2.34Miscellaneous Outstanding Shares18,390,000Free Float14,304,000Market Cap$10.31 million OptionableOptionable Beta1.31 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. William V. Williams M.D. (Age 69)CEO, President & Director Comp: $785.3kMr. Gadi Levin B.Com. (Age 51)C.A., CPA, M.B.A., CFO & Corporate Secretary Comp: $304.46kDr. Miguel A. Lopez-Lago Ph.D. (Age 55)Chief Scientific Officer Comp: $298.9kDr. Giuseppe Del Priore M.D. (Age 62)M.P.H., MPH, Chief Medical Officer Comp: $492.5kDr. Charles Louis Wiseman FACP (Age 78)M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board Comp: $241.14kKey CompetitorsNabriva TherapeuticsNASDAQ:NBRVQilian International Holding GroupNASDAQ:BGMvTv TherapeuticsNASDAQ:VTVTAadi BioscienceNASDAQ:AADILexaria BioscienceNASDAQ:LEXXView All Competitors BCTX Stock Analysis - Frequently Asked Questions How have BCTX shares performed this year? BriaCell Therapeutics' stock was trading at $5.85 on January 1st, 2024. Since then, BCTX stock has decreased by 90.4% and is now trading at $0.5605. View the best growth stocks for 2024 here. How were BriaCell Therapeutics' earnings last quarter? BriaCell Therapeutics Corp. (NASDAQ:BCTX) released its quarterly earnings data on Friday, June, 14th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.66. When did BriaCell Therapeutics IPO? BriaCell Therapeutics (BCTX) raised $15 million in an initial public offering on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. How do I buy shares of BriaCell Therapeutics? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCTX) was last updated on 9/15/2024 by MarketBeat.com Staff From Our PartnersInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
